Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $25.97 USD
Change Today -1.09 / -4.03%
Volume 1.5M
DEPO On Other Exchanges
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

depomed inc (DEPO) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/16/15 - $27.24
52 Week Low
08/1/14 - $9.85
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DEPOMED INC (DEPO)

depomed inc (DEPO) Related Businessweek News

No Related Businessweek News Found

depomed inc (DEPO) Details

Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of royalty and milestone producing license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.

324 Employees
Last Reported Date: 02/26/15
Founded in 1995

depomed inc (DEPO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $620.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $374.8K
Senior Vice President and General Counsel
Total Annual Compensation: $396.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $211.9K
Senior Vice President of Business Development
Total Annual Compensation: $316.7K
Compensation as of Fiscal Year 2014.

depomed inc (DEPO) Key Developments

Depomed, Inc. Enters into Settlement Agreement with Actavis, Inc

Depomed Inc. announced it has entered into a settlement agreement with Actavis Inc. in Depomed's patent infringement litigation related to Actavis's Abbreviated New Drug Application seeking approval to market generic versions of Depomed's Gralise® (gabapentin) 300 mg and 600 mg tablets. The settlement permits Actavis to begin selling generic versions of Gralise on January 1, 2024, or earlier under certain circumstances. The settlement dismisses Actavis's pending appeal with the United States Court of Appeals for the Federal Circuit of the August 2014 trial court decision finding all seven Depomed patents asserted in the litigation, which expire between 2016 and February 2024, to be valid and infringed. The settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of orders dismissing the appeal and related federal district court litigation.

DepoMed Inc. Proposes Amendments to Amended and Restated Articles of Incorporation

DepoMed Inc. proposed amendments to the company's amended and restated articles of incorporation to increase the number of authorized shares of common stock by 100,000,000 shares, to its annual meeting of shareholders will be held on May 12, 2015.

Depomed Gets $575 Million Debt Facility from Deerfield and Pharmakon

Depomed reported that it has entered into a definitive agreement with Deerfield and Pharmakon Advisors to borrow $575 million. The Company noted that the proceeds of the loan will be used to fund the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals which Depomed announced on January 15. Upon signing the acquisition agreement in January, Depomed placed $500 million into escrow. The escrowed amount and the proceeds of this loan will satisfy the $1.05 billion acquisition price and fees related to the transactions. The loan will have a term of seven years, will be secured by Depomed's assets and will bear interest at the rate of 9.75% over three month LIBOR, with a floor of 1% and subject to certain caps. The loan can be prepaid under certain conditions and at Depomed's discretion any time after the second anniversary. $100 million of the facility may be paid down after one year. The loan financing and the acquisition of NUCYTNA are subject to customary closing conditions, including HSR review. Depomed now expects the loan financing and the acquisition to close in April 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DEPO:US $25.97 USD -1.09

DEPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acorda Therapeutics Inc $34.49 USD -0.19
Biocon Ltd 465.80 INR -5.60
Emergent Biosolutions Inc $29.49 USD -0.67
Insys Therapeutics Inc $60.78 USD -0.21
Nektar Therapeutics $11.95 USD -0.18
View Industry Companies

Industry Analysis


Industry Average

Valuation DEPO Industry Range
Price/Earnings 13.1x
Price/Sales 3.9x
Price/Book 4.2x
Price/Cash Flow 10.9x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEPOMED INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at